(NewsDirect)
NEW YORK, NY /NewsDirect / September 27th, 2023 / Best Growth Stocks, a leadingindependent equity research and corporate access firm focused onfinding and reporting on the best growth stocks utilizing exclusiveai-assisted research recently issued an extensive analysis on AvaloTherapeutics Inc a clinical-stage biotechnology company focused on thetreatment of immune dysregulation by developing therapies that targetthe LIGHT-signaling network.
Avalo Therapeutics Inc (NASDAQ: AVTX) recentlyannounced the elimination of $35 million in debt paving the way forfuture growth and innovation.
Best Growth Stock's full report breaks throughthe noise and offers a full comprehensive and easy-to-understandanalysis of Avalo’s securities, recent events, earnings, pipeline,and more.
Accessthis full report: https://bestgrowthstocks.com/access-avtx-analysis/ (copy and paste to browser may be required)
About AvaloTherapeutics
Avalo Therapeutics is a clinical stage biotechnology companyfocused on the treatment of immune dysregulation by developingtherapies that target the LIGHT-signaling network.
LIGHT (Lymphotoxin-like,exhibits Inducible expression, and competes with HSV Glycoprotein Dfor Herpesvirus Entry Mediator (HVEM), a receptor expressed by Tlymphocytes; also referred to as TNFSF14) is an immunoregulatorycytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), andlymphotoxin ? receptor (TNFRSF3), form an immune regulatory networkwith two co-receptors of herpesvirus entry mediator, checkpointinhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (theLIGHT-signaling network). Accumulating evidence points to thedysregulation of the LIGHT-signaling network as a disease-drivingmechanism in autoimmune and inflammatory reactions in barrier organs.Therefore, we believe reducing LIGHT levels can moderate immunedysregulation in many acute and chronic inflammatory disorders.
Avalo has an experiencedleadership team with decades of successful leadership in drugdevelopment in the biotech and pharma industries. The team is led byDr. Garry Neil, MD, Chief Executive Officer and Chairman of the Board,who brings a wealth of experience leading teams who have successfullybrought drugs to the market, including serving as Group President,Pharmaceutical R&D and Corporate VP of Science & Technology atJohnson & Johnson. Additionally, Dr. Neil served as Chairman ofthe Board of Arena Pharmaceuticals Inc., which was acquired by PfizerInc. for $6.7 billion in March of 2022. Dr. Neil currently serves onthe board of directors of Celldex Therapeutics.
For more informationabout Avalo, please visit https://www.avalotx.com/ .
InvestorInquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
About Best Growth Stocks
Best Growth Stocks is aleading independent equity research and corporate access firm focusedon finding and reporting on the best growth stocks utilizing ourexclusive ai-assisted research. BGS is also a financial news provider,focused on giving investors direct access to CEOs of promising,publicly-traded companies, and market experts. Our CEO interviews aimto answer the questions that rest on the minds of current and futureshareholders. Not to be construed as financial advice. Consult with alicensed financial advisor prior to any financial decisions.
MediaContact
Best Growth Stocks
Steve Macalbry, Senior Editor
SOURCE:BestGrowthStocks.Com
Contact Details
BestGrowth Stocks
Steve Macalbry
Copyright (c) 2023 TheNewswire - All rights reserved.